Barbara Gayle Duncan Atea Pharmaceuticals, Inc. (AVIR) insider trading activity

Barbara Gayle Duncan is of Atea Pharmaceuticals, Inc.. Currently has a direct ownership of 62,750 shares of AVIR, which is worth approximately $228,410. The most recent transaction as insider was on Jun 20, 2025, when has been sold 29,600 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 62.8K

89.29% 3M change

89.29% 12M change

Total Value Held $228,410

Barbara Gayle Duncan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Jun 20 2025	BUY Exercise of conversion of derivative security	-	29,600 Added 32.05%	62,750 Common Stock
Jun 16 2024	BUY Exercise of conversion of derivative security	-	33,150 Added 50.0%	33,150 Common Stock

Also insider at

IMMU

IMMUNOMEDICS INC

Director

FUSN

Fusion Pharmaceuticals Inc. Healthcare

OVID

Ovid Therapeutics Inc. Healthcare

JNCE

Jounce Therapeutics, Inc. Healthcare

Director

ADAP

Adaptimmune Therapeutics PLC Healthcare

Director

HALO

HALOZYME THERAPEUTICS, INC. Healthcare

BGD